Recent studies have identified that METTL14/m6A-mediated epitranscriptomic alterations disrupt ADRB signaling in adipose tissue, contributing to the development of obesity, NAFLD and other metabolic disorders (Kang et al., 2023). The gene discussed is METTL14; the disease is metabolic dysfunction-associated steatotic liver disease.